PUBLISHER: DelveInsight | PRODUCT CODE: 1173619
PUBLISHER: DelveInsight | PRODUCT CODE: 1173619
DelveInsight's "Immune Thrombocytopenic Purpura (ITP) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of ITP historical and forecasted epidemiology as well as the ITP market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.
The ITP market report provides current treatment practices, emerging drugs, and market share of individual therapies, current and forecasted 7MM ITP market size. The report also covers a descriptive overview of ITP, SWOT analysis, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
ITP, previously called immune thrombocytopenic purpura or idiopathic thrombocytopenic purpura, is an autoimmune disorder that occurs when the body attacks its platelets and destroys them quickly. ITP is a disorder that affects the overall number of blood platelets rather than their function. The normal platelet level in adults is between 150,000/mm3 and 450,000/mm3. Platelet counts below 50,000/mm3 increase the risk of dangerous bleeding from trauma; counts below 20,000/mm3 increase the risk of spontaneous bleeding.
ITP is caused by various etiologies characterized by increased platelet destruction and impaired production, resulting in a decreased platelet count. Primary ITP is idiopathic, whereas secondary ITP is linked to an underlying condition. When PNH is associated with AA, most patients express only a small PNH clone (<10%). Physicians could find clinical and/or biological evidence of hemolysis associated with two or three cytopenias (Hb <10 g/dL, neutrophils <1,000/μL, platelets <80,000/μL). In general, bone marrow failure dominates the clinical picture.
ITP can also be classified by disease duration. ITP has been categorized into new-onset (acute) for those diagnosed within the last 3 months, persistent for those between 3 months and 12 months, and chronic for those who have had the disease for more than 1 year. In acute ITP cases, patients usually suffer from bruising; petechia, nosebleeds, and bleeding gums may occur if the platelet count is below 20,000/mm3 compared with a normal range of 150,000-400,000/mm3. In extreme cases, patients with ITP may bleed into the lungs, brain, or other vital organs, leading to subarachnoid, intracerebral hemorrhage, or other internal bleeding are possible severe complications of this disease.
The epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of ITP, Age-specific Diagnosed Prevalent Cases of ITP and Gender-specific Diagnosed Prevalent Cases of ITP scenario in the 7MM covering the United States, the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan from 2019 to 2032.
Rilzabrutinib (PRN-1008) is an orally administered reversible covalent inhibitor of Bruton tyrosine kinase (BTK). BTK is an essential signaling element downstream of the B-cell receptor (BCR), Fc-gamma receptor, and Fc-epsilon receptor pathways. BTK activation is critical for B-cell activation and maturation. BTK also regulates antibody-mediated activation of other immune cells, such as macrophages, neutrophils, and mast cells, through Fc receptor signaling.
Efgartigimod (ARGX-113) is an investigational therapy for IgG-mediated autoimmune diseases and was designed to exploit the natural interaction between IgG antibodies and the recycling receptor FcRn Argenx, designed efgartigimod to degrade circulating disease-causing autoimmune antibodies and has potential in many large and orphan indications, namely multiple sclerosis, ITP, systemic lupus erythematosus, myasthenia gravis, and skin-blistering diseases.
ITP is characterized by low platelet counts and an increased tendency to bleed. Although ITP generally presents as a subtle-onset, chronic disorder in adults, clinical manifestations can range from petechia, purpura, and bruising to overt bleeding, such as gastrointestinal or intracranial hemorrhaging. When treatment is deemed necessary, typical first-line therapies include corticosteroids, intravenous immunoglobulin (IVIg), and Rho (D) immune globulin, also referred to as anti-D immune globulin (IV anti-D). Relapse or failure to respond to these drugs may necessitate second-line treatment, including various medical options and splenectomy.
In ITP, the first-line treatment option is generally corticosteroids. The recommended prednisone dose is 1 mg/kg/day orally for up to 21-28 days depending upon the response, followed by slow tapering. More prominent platelet responses have been reported with repeated pulses of high-dose dexamethasone 40 mg daily for 4 days.
Also, intravenous immunoglobulin or intravenous anti-D (Rho [D] immune globulin) is used as an initial treatment with or without steroids. Most adult patients will relapse after initial treatment (or are refractory to first-line therapy) and require second-line therapy. Intravenous immunoglobulin (IVIG) therapy is administered to patients requiring rapid or urgent elevation of platelet count (e.g., intraoperative or life-threatening bleeding). IVIg increases the platelet count in 70-80% of treated patients, often within days. Several IVIg regimens have been employed, but many hematologists prefer the convenience of a 1 g/kg/day infusion for 1-2 days. Anti-D immunoglobulin (anti-D) binds to Rh (D) antigen on erythrocytes, thereby leading to the clearance of antibody-coated cells and inhibiting the clearance of opsonized platelets by the reticuloendothelial system. Therefore, anti-D is effective only in RhD-positive individuals, and anti-D has been reported effective in approximately 50-70% of patients treated with this agent.
This section provides the total ITP market size and market size by therapies in the United States.
The total ITP market size and market size by therapies in EU4 (Germany, France, Italy, Spain) and the United Kingdom are provided in this section.
The total ITP market size and market size by therapies in Japan are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the ITP market or expected to get launched in the market during the study period 2019-2032. The analysis covers the ITP market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in Phase II and Phase III stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers detailed information on collaborations, acquisitions, merger, licensing, and patent details for ITP emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
We perform competitive market Intelligence analysis of the ITP market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.